Esperion Therapeutics Inc (ESPR) concluded trading on Thursday at a closing price of $2.32, with 4.17 million shares of worth about $9.67 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.43% during that period and on December 26, 2024 the price saw a gain of about 0.87%. Currently the company’s common shares owned by public are about 195.44M shares, out of which, 195.08M shares are available for trading.
Stock saw a price change of 7.41% in past 5 days and over the past one month there was a price change of -9.73%. Year-to-date (YTD), ESPR shares are showing a performance of -22.41% which decreased to -10.08% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.58 but also hit the highest price of $3.94 during that period. The average intraday trading volume for Esperion Therapeutics Inc shares is 5.60 million. The stock is currently trading -15.18% below its 20-day simple moving average (SMA20), while that difference is down -4.14% for SMA50 and it goes to 3.63% higher than SMA200.
Esperion Therapeutics Inc (NASDAQ: ESPR) currently have 195.44M outstanding shares and institutions hold larger chunk of about 65.84% of that.
The stock has a current market capitalization of $457.12M and its 3Y-monthly beta is at 1.01. It has posted earnings per share of -$0.66 in the same period. It has Quick Ratio of 1.37. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 5.70% while standing at 12.99% over the month.
Stock’s fiscal year EPS is expected to rise by 85.28% while it is estimated to increase by 172.65% in next year. EPS is likely to shrink at an annualized rate of 16.90% for next 5-years, compared to annual growth of 23.09% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 18, 2024 offering a Neutral rating for the stock and assigned a target price of $4 to it. Coverage by Cantor Fitzgerald stated Esperion Therapeutics Inc (ESPR) stock as an Overweight in their note to investors on December 17, 2024, suggesting a price target of $8 for the stock. Stock get a Neutral rating from JP Morgan on November 20, 2023.
